BACKGROUND TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. METHODS 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and triple negative breast cancer (TNBC) were subjected to Sanger sequencing of exons 5-8 of the T...

Breast cancer is one of the leading causes cancer-related mortality among women. Multiple subtypes exist for tumor biology, but triple-negative breast (TNBC) lacks expression estrogen receptor, progesterone and human epidermal growth factor. TNBC accounts 20% cancers most aggressive associated with an earlier age susceptibility, racial ethnic differences, limited targeted therapies. African Ame...

Background: Triple-negative breast cancers (TNBC) are defined as breast cancers with lack of estrogen and progesterone receptors and no overexpression of human epidermal growth factor receptor 2 (HER2). This study was performed to determine the frequency and pathologic features of TNBC in Iranian patients. Subjects and Methods: This cross-sectional study was performed on patients with breast ca...

BACKGROUND Src, a non-receptor tyrosine kinase is elevated in cancer with expression and activity correlated with cell proliferation, adhesion, survival, motility, metastasis and angiogenesis. There is limited data on Src expression and subcellular localization in breast cancer and no information about expression in racial/ethnic groups. METHODOLOGY/PRINCIPAL FINDINGS The present study evalua...

OBJECTIVE Triple-negative breast cancer (TNBC) patients with truly chemosensitive disease still represent a minority among all TNBC patients. The aim of the present study is to identify microRNAs (miRNAs) that correlate with TNBC chemoresistance. METHODS In this study, we conducted miRNAs profile comparison between triple-negative breast cancer (TNBCs) and normal breast tissues by microRNA ar...

Tumors act systemically to sustain cancer progression, affecting the physiological processes in the host and triggering responses in the blood circulating cells. In this study, we explored blood transcriptional patterns of patients with two subtypes of HER2 negative breast cancers, with different prognosis and therapeutic outcome. Peripheral blood samples from seven healthy female donors and 29...

The epithelial-mesenchymal transition (EMT) plays an important role in breast cancer metastasis, especially in the most aggressive and lethal subtype, "triple-negative breast cancer" (TNBC). Here, we report that CD146 is a unique activator of EMTs and significantly correlates with TNBC. In epithelial breast cancer cells, overexpression of CD146 down-regulated epithelial markers and up-regulated...

HES1 is a transcriptional repressor involved in cell differentiation and proliferation as well as in various cancer developments, but its expression pattern and biological roles in breast cancer have not been examined. In this study, we assessed HES1 expression in breast cancer tissues using immunohistochemistry and Western blot analyses and investigated HES1 function using MTT and Matrigel inv...

Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of cases. The prognosis for advanced TNBC usually poor, with median overall survival approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 agents are emerging an option to treat TNBC. A panel 6 national experts active interest in convened online. Panel member...

INTRODUCTION • Triple-negative breast cancer (TNBC) represents 10%–20% of invasive breast cancers1 and has a very poor prognosis.2 There is a particular unmet need in TNBC, with a lack of clinically established targeted therapies3; chemotherapy is the only option for metastatic TNBC.4 • To facilitate access to new treatments, it is increasingly important to understand payer evidence needs in ad...